The purpose of this study is to learn whether giredestrant is more effective than other endocrine therapies in patients with estrogen receptor-positive, HER2-negative early breast cancer who have completed neoadjuvant chemotherapy and who have had surgery.
COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4
North Carolina (Statewide)
Anureet Copeland
UNC Hospitals - Rex
Clinical or Medical
Interventional
Cancer (Breast)
21-3237
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
